Semaglutide

Amycretin shows potentially superior weight loss (up to 24.3% in Phase 1b/2a) compared to semaglutide (14.9% in STEP 1), driven by its dual GLP-1/amylin mechanism in a single molecule. The ability to offer both injectable and oral formulations without fasting restrictions is a significant advantage. However, these are early-phase results with small sample sizes and short duration. Semaglutide remains the proven, FDA-approved standard with cardiovascular benefit and extensive safety data. Amycretin is Novo Nordisk's most promising pipeline asset, but Phase 3 confirmation is needed before definitive comparisons can be made.

Bioglutide (NA-931) presents a novel quadruple-agonist mechanism that is scientifically ambitious, targeting GLP-1, GIP, glucagon, and IGF-1 receptors in a single oral molecule. The Phase 2 data (14.8% weight loss at 13 weeks with reported muscle preservation) are remarkable if confirmed, suggesting rapid, substantial weight loss that approaches semaglutide's 68-week results in just a fraction of the time. However, extreme caution is warranted. The data come from a small (125-patient), short (13-week) trial presented at conferences but not yet peer-reviewed in a major journal. The muscle preservation claims lack published DEXA data. Semaglutide remains the proven standard with massive evidence, cardiovascular benefit, and years of real-world safety data. Bioglutide's claims require rigorous Phase 3 validation before meaningful clinical comparison.

These peptides serve entirely different purposes and are not interchangeable. Semaglutide is an FDA-approved pharmaceutical with massive clinical validation for diabetes and obesity. BPC-157 is a preclinical research peptide studied for tissue healing without any human clinical trials. The comparison highlights the enormous evidence gap between a fully validated drug and a promising preclinical compound. For metabolic disease, semaglutide has unequivocal evidence. For tissue healing research, BPC-157 has intriguing preclinical data that awaits human translation.

CagriSema demonstrates meaningfully greater weight loss than semaglutide alone (20.4% vs 14.9%), driven by the complementary amylin pathway from cagrilintide. REDEFINE 1 showed CagriSema was superior to semaglutide alone, cagrilintide alone, and placebo. However, semaglutide has proven cardiovascular benefit (SELECT), 7+ years of safety data, oral formulation options, and established availability. CagriSema represents the next step for patients who need greater weight loss than semaglutide alone can provide, once it becomes available.

Ecnoglutide's biased GLP-1 signaling represents a scientifically novel approach, and SLIMMER Phase 3 data (15.4% weight loss at 48 weeks) are comparable to semaglutide's STEP 1 results (14.9% at 68 weeks). However, the comparison is limited by population differences (Chinese adults vs global populations), different trial durations, and vastly different evidence bases. Semaglutide has proven cardiovascular benefit, 7+ years of safety data, and global availability. Ecnoglutide may offer a competitive alternative in certain markets, particularly China, but its biased signaling advantage has not yet been demonstrated in head-to-head comparison with semaglutide.

Semaglutide is substantially superior to exenatide in weight loss efficacy (14.9% vs 2-4%), glycemic control (SUSTAIN 3 head-to-head), cardiovascular outcomes (proven superiority vs non-inferiority only), and dosing convenience (pre-filled weekly pen vs reconstitution). Exenatide holds historical significance as the first GLP-1 agonist (FDA 2005) and may still serve as a lower-cost alternative in markets where newer agents are unavailable. However, for most clinical applications, semaglutide has effectively superseded exenatide.

Semaglutide is superior to liraglutide across every major clinical dimension. The STEP 8 head-to-head trial demonstrated nearly 2.5-fold greater weight loss with semaglutide (15.8% vs 6.4%) and a lower discontinuation rate (3.2% vs 12.6%). Semaglutide also offers once-weekly dosing (vs daily), broader cardiovascular evidence (SELECT trial in non-diabetic obesity), and both injectable and oral formulations. Liraglutide retains value as a lower-cost option with a longer safety track record, and it remains the only GLP-1 approved for adolescent obesity (ages 12+).

Semaglutide remains the proven standard with FDA approval, cardiovascular benefit, and the broadest evidence base of any GLP-1 agonist. MariTide offers a genuinely differentiated approach with three key innovations -- monthly dosing, an antibody-peptide conjugate platform, and GIP receptor antagonism (vs the GIP agonism used by tirzepatide). The phase 2 NEJM-published data showing up to 20% weight loss at 52 weeks with monthly injections and GI side effects concentrated at the first dose are particularly promising. If phase 3 confirms these results, MariTide could become the preferred option for patients who want the least frequent dosing schedule.

Semaglutide for proven efficacy with extensive safety data and global availability; mazdutide shows promise for potentially greater weight loss through dual agonism but requires broader clinical validation

MET-097i represents a potentially disruptive approach to GLP-1 therapy with its ultra-long half-life enabling once-monthly dosing. Phase 2b data shows competitive weight loss (14.1% placebo-subtracted), and the convenience of monthly dosing could significantly improve treatment adherence. However, semaglutide remains the gold standard with proven efficacy, cardiovascular benefit, 7+ years of safety data, multiple formulations, and FDA approval. MET-097i's clinical value will ultimately depend on Phase 3 confirmation and whether the convenience advantage translates to better real-world outcomes. Pfizer's acquisition of Metsera signals strong commercial interest in the once-monthly GLP-1 concept.

Orforglipron represents a potential paradigm shift as the first oral non-peptide GLP-1 agonist without fasting restrictions, and it demonstrated superiority over oral semaglutide in the head-to-head ACHIEVE-3 trial for both HbA1c and weight loss. However, injectable semaglutide (2.4 mg) still produces greater absolute weight loss (14.9% vs 12.4%) and has proven cardiovascular benefit from SELECT, plus years of real-world safety data. The choice depends on whether oral convenience or maximum proven efficacy is the priority.

Semaglutide is the established gold standard with FDA approval, proven cardiovascular benefit, extensive clinical data, and multiple formulation options. Retatrutide's triple agonism shows promise for greater weight loss and liver fat reduction, but remains investigational with Phase 2 data only. Phase 3 results will determine whether retatrutide's early advantages translate into meaningful clinical superiority.

Semaglutide is the established standard with three FDA approvals, massive clinical evidence, and proven cardiovascular outcomes. Survodutide represents the next-generation approach, adding glucagon receptor agonism to GLP-1 signaling for potentially greater weight loss and a unique MASH indication. However, survodutide remains in Phase 3 without regulatory approval. For current clinical use, semaglutide has unmatched validation. For the future of metabolic therapeutics, survodutide's dual mechanism targeting both caloric intake and energy expenditure could prove transformative if Phase 3 data confirm the Phase 2 promise.

Tirzepatide demonstrates greater weight loss and glycemic control than semaglutide in clinical trials, achieving up to 20.9% body weight reduction versus 14.9-16.0% with semaglutide. However, semaglutide has proven cardiovascular benefit (SELECT trial), longer post-marketing safety data, and an oral formulation option. Both are FDA-approved, well-tolerated, and represent major advances in metabolic medicine. The choice between them depends on clinical priorities: maximum weight loss favors tirzepatide, while cardiovascular risk reduction and formulation flexibility favor semaglutide.

Semaglutide is the clear choice for patients who need treatment today, with FDA approval, proven cardiovascular benefit, and over 7 years of safety data. VK2735 shows promising early results, with rapid weight loss in short-term phase 2 trials that suggest it could be competitive with established agents. Its dual GLP-1/GIP mechanism and development of both injectable and oral formulations position it as a potential future competitor, but it remains years from potential approval and lacks long-term efficacy and safety data.

Semaglutide is the proven standard with extensive Phase 3, real-world, and cardiovascular outcomes data across tens of thousands of patients. Zovaglutide offers the compelling advantage of once-monthly dosing (12-13 injections per year vs 52) with early Phase 2 data showing competitive weight loss and low GI side effect rates. However, zovaglutide has only 303 patients studied over 24 weeks, no Phase 3 data, and no long-term safety information. For current treatment decisions, semaglutide is the clear choice. Zovaglutide represents an important advance in dosing convenience if Phase 3 confirms the Phase 2 results.